Lyell Immunopharma (NASDAQ:LYEL) Shares Up 4.9%

Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) shares rose 4.9% on Thursday . The stock traded as high as $2.17 and last traded at $2.16. Approximately 21,770 shares changed hands during trading, a decline of 98% from the average daily volume of 972,663 shares. The stock had previously closed at $2.06.

Analysts Set New Price Targets

Separately, HC Wainwright reduced their price objective on Lyell Immunopharma from $8.00 to $6.00 and set a "buy" rating for the company in a research note on Thursday, February 29th.

Lyell Immunopharma Stock Up 1.5 %

The firm has a market cap of $531.06 million, a price-to-earnings ratio of -2.34 and a beta of -0.56. The company has a 50-day moving average price of $2.16 and a 200 day moving average price of $1.94.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last issued its earnings results on Wednesday, February 28th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.01. The business had revenue of $0.01 million during the quarter, compared to analysts' expectations of $4.96 million. Lyell Immunopharma had a negative return on equity of 32.67% and a negative net margin of 180,486.14%. Equities analysts forecast that Lyell Immunopharma, Inc. will post -0.91 EPS for the current year.

Institutional Trading of Lyell Immunopharma

Several hedge funds and other institutional investors have recently modified their holdings of LYEL. Tower Research Capital LLC TRC raised its holdings in shares of Lyell Immunopharma by 251.9% during the first quarter. Tower Research Capital LLC TRC now owns 10,687 shares of the company's stock worth $25,000 after acquiring an additional 7,650 shares in the last quarter. Advisor Group Holdings Inc. raised its holdings in Lyell Immunopharma by 3,125.3% during the fourth quarter. Advisor Group Holdings Inc. now owns 7,902 shares of the company's stock valued at $27,000 after buying an additional 7,657 shares in the last quarter. Virtu Financial LLC bought a new position in Lyell Immunopharma during the fourth quarter valued at about $29,000. Ethic Inc. acquired a new stake in shares of Lyell Immunopharma in the first quarter valued at about $30,000. Finally, Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Lyell Immunopharma in the fourth quarter valued at about $31,000. 66.05% of the stock is currently owned by hedge funds and other institutional investors.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.